Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROBE TRIAL (Pilot Rilpivirine Observational Evaluation) Monocenter, national, prospective, open label, pilot, proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients.

Trial Profile

PROBE TRIAL (Pilot Rilpivirine Observational Evaluation) Monocenter, national, prospective, open label, pilot, proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilpivirine (Primary) ; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms PROBE
  • Most Recent Events

    • 20 Feb 2016 Primary endpoint has been met, (Non-inferiority of the virological response between treatment groups according to FDA snapshot approach, at 24 and 48 weeks), according to results published.
    • 20 Feb 2016 Results published in the JAIDS.
    • 24 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to results published.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top